← Back to Search
Congestive Heart Failure In Patients Treated With Doxorubicin
S. Swain, F. Whaley, M. Ewer
Published 2003 · Medicine
Download PDFAnalyze on Scholarcy
Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug. A large‐scale study that retrospectively evaluated the cardiotoxicity of doxorubicin reported that an estimated 7% of patients developed doxorubicin‐related congestive heart failure (CHF) after a cumulative dose of 550 mg/m2. To assess whether this estimate is reflective of the incidence in the broader clinical oncology setting, the authors evaluated data from three prospective studies to determine both the incidence of doxorubicin‐related CHF and the accumulated dose of doxorubicin at which CHF occurs.
This paper references
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
M. Ryberg (1998)
Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
E. Herman (1981)
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
N. Iliskovic (1997)
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
S. Lipshultz (1997)
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.
C. Myers (1983)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
E. Herman (1999)
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
J. Speyer (1992)
Advanced small cell lung cancer treated with CAV (cyclophosphamide-Adriamycin vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard
J Feldmann (1992)
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
S. Swain (1997)
Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
P. Working (1999)
CLINICAL AND PHARMACOLOGIC INVESTIGATION OF THE EFFECTS OF α‐TOCOPHEROL ON ADRIAMYCIN CARDIOTOXICITY *
S. Legha (1982)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
K. K. Jain (1985)
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)
Advanced small cell lung cancer treated with CAV (cyclophosphamide-Adriamycin ϩ vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard)
J Feldmann (1992)
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
B. V. Jensen (2002)
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.
C. Myers (1977)
Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.
J. Mason (1978)
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.
P. M. Kanter (1993)
Early Detection of Anthracycline-Induced Cardiotoxicity by Radionuclide Angiocardiography
J. Suzuki (1999)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
V. Valero (1999)
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
This paper is referenced by
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
R. Pettengell (2018)
Doxorubicin‐induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy
Michael P Catanzaro (2019)
Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
V. Todorova (2012)
Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression
S. Gupta (2018)
Effects of chemotherapy and blocking activin receptor signaling on skeletal muscle size, oxidative capacity and function
Aino Poikonen (2016)
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
R. De Sanctis (2015)
Cardiogenic Shock 14 Years Post Anthracyclines
S. Schmidt (2018)
Engagement with tNOX ( ENOX 2 ) to Inhibit SIRT 1 and Activate p 53-Dependent and-Independent Apoptotic Pathways by Novel 4 , 11-Diaminoanthra [ 2 , 3-b ] furan-5 , 10-diones in Hepatocellular Carcinoma Cells
Chia-Yang Lin (2019)
Trial Designs Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy : Rationale and Design of the ERIC-ONC Study — A Single-Center , Blinded , Randomized Controlled Trial
Robin Chung (2016)
THE PLACE OF ECHOCARDIOGRAPHY IN THE ASSESSEMENT OF PATIENTS RECEIVING CARDIOTOXIC CANCER THERAPIES: NEW HORIZONS
C. Mornoș (2011)
Deubiquitination : does the answer to cardiotoxicity lie within the ubiquitin proteasome pathway
Temitope Richard Ogundipe (2017)
Review Statins in Anthracycline-induced Cardiotoxicity: Rac and Rho, and the Heartbreakers Official Journal of the Cell Death Differentiation Association
Christian Henninger (2017)
Cardiomiopatía inducida por antraciclinas en pacientes tratadas por cáncer de mama
L. Alarcón (2012)
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice
L. Santucci (2007)
Clinical pharmacology of cancer therapies in older adults
A. Hurria (2008)
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
S. Verma (2008)
Autophagy Upregulation Reduces Doxorubicin-Induced Cardiotoxicity
Balindiwe J. N. Sishi (2015)
Ironing out doxorubicin-related cardiotoxicity
V. Subramaniam (2003)
Cancer and ageing: a nexus at several levels
L. Balducci (2005)
Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin.
C. Fox (2020)
Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients
L. Haupt (2020)
Toxicogenetic study of Persea americana fruit pulp oil and its effect on genomic instability.
H. Nicolella (2017)
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
I. Kim (2017)
Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline Therapy.
K. Hatazawa (2018)
A novel approach to drug development in heart failure: towards personalized medicine.
Licette C. Y. Liu (2014)
Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculoprotection in Personalized Therapy
R. Madonna (2019)
Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique
S. Edérhy (2014)
Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications.
Lei Xi (2012)
The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients
B. Pitekova (2016)
Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.
A. Malato (2010)
Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.
P. Lancellotti (2013)
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma
M. Jamal-Hanjani (2011)See more